title: Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis.
abstract: OBJECTIVE
  To assess the link between very early erythromycin exposure and pyloric stenosis in young infants.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  Medicaid or TennCare (Tennessee's program for Medicaid enrollees and uninsured individuals) births in Tennessee from 1985 to 1997. Cases of infants with a hospital discharge diagnosis of pyloric stenosis and an associated surgical procedure code were used. Erythromycin exposure and other antibiotic exposure between 3 and 90 days of life were identified from prescription files.
  
  
  METHODS
  Hospital discharge diagnosis of pyloric stenosis, and an associated surgical procedure code.
  
  
  RESULTS
  Of 933 239 births in Tennessee during the study period, 314 029 were enrolled in Medicaid. Among these infants, 804 (2.6/1000 infants) met the criteria for pyloric stenosis. Very early exposure to erythromycin (between 3 and 13 days of life) was associated with a nearly 8-fold increased risk of pyloric stenosis (adjusted incident rate ratio, 7.88; 95% confidence interval, 1.97-31.57). No increased risk of pyloric stenosis was seen in infants exposed to erythromycin after 13 days of life or in infants exposed to antibiotics other than erythromycin.
  
  
  CONCLUSIONS
  The significant increase in pyloric stenosis in children with very early exposure to erythromycin is consistent with reports of other investigators. The risks and benefits of erythromycin should be weighed carefully prior to initiating such therapy in young infants.
authors.affiliation: Department of Pediatrics, Division of General Pediatrics, Vanderbilt University School of Medicine, Suite 5028 MCE, Nashville, TN 37232-8555, USA. william.cooper@mcmail.vanderbilt.edu
authors.forename: William O
authors.initials: WO
authors.lastname: Cooper
authors.forename: Marie R
authors.initials: MR
authors.lastname: Griffin
authors.forename: Patrick
authors.initials: P
authors.lastname: Arbogast
authors.forename: Gerald B
authors.initials: GB
authors.lastname: Hickson
authors.forename: Shiva
authors.initials: S
authors.lastname: Gautam
authors.forename: Wayne A
authors.initials: WA
authors.lastname: Ray
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D015331:Cohort Studies; D004917:Erythromycin / Q000009:adverse effects*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D006984:Hypertrophy / Q000139:chemically induced; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D007239:Infections / Q000188:drug therapy; D008297:Male; D011707:Pyloric Stenosis / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D011708:Pylorus / Q000473:pathology*; D012189:Retrospective Studies; D012307:Risk Factors; D013714:Tennessee / Q000453:epidemiology; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D005765:Gastrointestinal Agents; D004917:Erythromycin